Funded Startups in Weston
Spear Bio’s $45M (2024-07-29) is the only disclosed round above $40M in the Weston list, dwarfing the next-largest disclosed amount of $16M from Prosper He…
Spear Bio’s $45M (2024-07-29) is the only disclosed round above $40M in the Weston list, dwarfing the next-largest disclosed amount of $16M from Prosper Health (2025-01-23) and putting the top three ($16M, $13M, $9M) into a different scale tier than the rest. The rounds also cluster around recent years: the 10 most recent entries span 2022-11-16 (Dumpling Daughter) to 2026-07-08 (Hyperion Surgical), with multiple financings in 2025 (Prosper Health, Phoenix Technologies, FrodoBots Lab, ZyVersa Therapeutics). Sector mix is concentrated in Health Care and adjacent work: Health Care appears in Hyperion Surgical, ZyVersa Therapeutics, and Prosper Health (3 entries), while Biotechnology shows up twice (Spear Bio and Spear Bio’s category listing, plus Spear Bio itself as Biotechnology; overall, Biotechnology is present in Spear Bio). Stage labeling is mixed but “Series Unknown” is the dominant classification (5 of 10 entries), which affects how much can be inferred from stage rather than timing.
Most recent rounds
10 shownRelated listings
Frequently asked
What stands out by disclosed round size, and where is the cutoff versus the rest?
The largest disclosed round is Spear Bio’s $45M on 2024-07-29; it sits well above the remaining disclosed amounts. The next-largest disclosed amount is Prosper Health’s $16M (2025-01-23), and the rest of the disclosed rounds fall below $10M, including Hyperion Surgical at $13M (2026-07-08) and DataCebo at $9M (2023-12-07).
How concentrated are these financings in time, especially among the most recent entries?
Four of the 10 entries are dated in 2025: Prosper Health ($16M, 2025-01-23), ZyVersa Therapeutics ($2M, 2025-03-06), FrodoBots Lab ($6M, 2025-02-13), and Phoenix Technologies ($5M, 2025-10-18). The list’s latest round is Hyperion Surgical on 2026-07-08 ($13M), while the earliest is Dumpling Daughter on 2022-11-16 ($920K).
Which stage labels dominate, and which are most informative for diligence?
“Series Unknown” appears 5 times out of 10, including Hyperion Surgical (2026-07-08, $13M) and Phoenix Technologies (2025-10-18, $5M), limiting stage comparability. The remaining named stages are Seed (FrodoBots Lab $6M on 2025-02-13; DataCebo $9M on 2023-12-07; Dumpling Daughter $920K on 2022-11-16; ProspectCloud $330K on 2023-09-15), plus one Series A (Spear Bio $45M on 2024-07-29).
Are there sectors or verticals over-represented in Weston’s recent funded set?
Health Care appears in three entries: Hyperion Surgical ($13M, 2026-07-08), ZyVersa Therapeutics ($2M, 2025-03-06), and Prosper Health ($16M, 2025-01-23). Biotechnology shows up in two entries (DataCebo is categorized as Data and Analytics rather than biotech, while Spear Bio is Biotechnology), making life-sciences adjacent themes more common than areas like Food and Beverage, which appears once (Dumpling Daughter $920K, 2022-11-16).
Is there a smaller-round outlier that helps define the lower edge of disclosed funding?
ProspectCloud is the smallest disclosed round at $330K (2023-09-15), which is notably below the next-lowest disclosed amount of $920K from Dumpling Daughter (2022-11-16). Below $1M also frames where the list transitions from seed-sized rounds (e.g., Dumpling Daughter $920K and ProspectCloud $330K) to larger disclosed amounts like DashFuel’s $3M (2023-06-06).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.